Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novartis AG (NYSE:NVS)

77.28
Delayed Data
As of Feb 24
 -0.17 / -0.22%
Today’s Change
66.93
Today|||52-Week Range
83.58
+6.10%
Year-to-Date
NVS Regular Dividend: NVS will begin trading ex-dividend on 03/01/17 with a $2.7464 dividend payable to shareholders of record as of 03/03/17.
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
Feb 24 / Zacks.com - Paid Partner Content
Gilead Sciences Raises Dividend by Double Digits
Feb 22 / GuruFocus News - Paid Partner Content
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, No...
Feb 24 / Zacks.com - Paid Partner Content
Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat
Feb 22 / MotleyFool.com - Paid Partner Content
Ring the Register With These Upcoming Spinoffs
Feb 24 / TheStreet.com - Paid Partner Content
ImmunoGen, Inc.: Waiting to Move FORWARD
Feb 21 / MotleyFool.com - Paid Partner Content
J.P. Marvel Investment Advisors, LLC Buys Akamai Technologies, Zayo Group Holdings, A...
Feb 23 / GuruFocus News - Paid Partner Content
Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today
Feb 21 / MotleyFool.com - Paid Partner Content
Here's Why Celgene's Latest Drug Is So Exciting
Feb 23 / MotleyFool.com - Paid Partner Content
Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today
Feb 21 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close77.45
Today’s open76.84
Day’s range76.82 - 77.35
Volume2,748,937
Average volume (3 months)3,435,906
Market cap$179.6B
Dividend yield3.52%
Data as of 4:02pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-61.91%
Earnings growth (this year)--
Earnings growth (next 5 years)+4.90%
Revenue growth (last year)-1.90%
P/E ratio27.2
Price/Sales3.61
Price/Book2.43

Competitors

 Today’s
change
Today’s
% change
MRKMerck+0.31+0.47%
PFEPfizer+0.20+0.59%
SNYSanofi+0.19+0.45%
GSKGlaxoSmithKline+0.07+0.17%
Data as of 4:02pm ET, 02/24/2017

Financials

Next reporting dateApril 25, 2017
EPS forecast (this quarter)$1.17
Annual revenue (last year)$48.4B
Annual profit (last year)$6.7B
Net profit margin13.83%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer
Joseph Jimenez
Chief Financial Officer
Harry Kirsch
Corporate headquarters
Basel, Basel-stadt (basle Town)

Forecasts


Search for Jobs